Cargando…

Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives

Endothelial dysfunction is a pathological entity that multiply affects the health status. Erectile dysfunction is being recognized as a condition that is strongly interrelated with endothelial dysfunction, being a vascular event itself. Oral pharmacotherapy for erectile dysfunction has provided us w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Konstantinopoulos, Angelis, Giannitsas, Konstantinos, Raptis, Spiros, Perimenis, Petros
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2007
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155232/ https://www.ncbi.nlm.nih.gov/pubmed/21901068

Ejemplares similares

Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
por: Giannitsas, Konstantinos, et al.
Publicado: (2008)

Erectile dysfunction – an update of current practice and future strategies
por: Kalsi, Jas, et al.
Publicado: (2013)

Erectile dysfunction and cancer: current perspective
por: Madan, Renu, et al.
Publicado: (2020)

Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons
por: Ferguson, James E., et al.
Publicado: (2013)

Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors
por: Al-Ameri, H, et al.
Publicado: (2009)

Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
por: Sung, Hyun Hwan, et al.
Publicado: (2012)

The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction
por: Smith-Harrison, L.I., et al.
Publicado: (2016)

Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction
por: Moschos, Marilita M, et al.
Publicado: (2016)

Mediterranean diet and erectile dysfunction: a current perspective
por: Di Francesco, Simona, et al.
Publicado: (2017)

Needs and Expectations of Patients with Erectile Dysfunction: An Update on Pharmacological Innovations in Phosphodiesterase Type 5 Inhibition with Focus on Sildenafil
por: Jannini, Emmanuele A., et al.
Publicado: (2018)

COVID-19 and Erectile Dysfunction: Endothelial Dysfunction and Beyond
por: Sansone, Andrea, et al.
Publicado: (2021)

Relationship between pseudoexfoliation syndrome and erectile dysfunction: a possible cause of endothelial dysfunction for development of erectile dysfunction
por: Gökce, Sabite Emine, et al.
Publicado: (2015)

Erectile Dysfunction: Causes, Diagnosis and Treatment: An Update
por: Mazzilli, Fernando
Publicado: (2022)

Effects of metformin on endothelial health and erectile dysfunction
por: Patel, Jay Pravin, et al.
Publicado: (2017)

Regenerative technology for future therapy of erectile dysfunction
por: Ryu, Ji-Kan, et al.
Publicado: (2012)

The future of penile prostheses for the treatment of erectile dysfunction
por: Lindsey, John P., et al.
Publicado: (2020)

A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil
por: Evans, Jeffery D, et al.
Publicado: (2015)

Penile vascular surgery for treating erectile dysfunction: Current role and future direction
por: Molodysky, Eugen, et al.
Publicado: (2013)

Erectile Dysfunction
Publicado: (2015)

Diagnosis and treatment of erectile dysfunction– a practical update
por: Persu, C, et al.
Publicado: (2009)

To the editor-an update on endovascular treatment of venogenic erectile dysfunction
por: Hoppe, Hanno, et al.
Publicado: (2022)

Current approaches to the diagnosis of vascular erectile dysfunction
por: Ma, Ming, et al.
Publicado: (2020)

Erectile dysfunction and central obesity: an Italian perspective
por: Corona, Giovanni, et al.
Publicado: (2014)

Erectile dysfunction: Doctors’ perspectives on patients’ concerns
por: Ji, Katherine L., et al.
Publicado: (2012)

Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction
por: Sadovsky, R, et al.
Publicado: (2009)

Phosphodiesterase type 5 inhibitors for the treatment of post-nerve sparing radical prostatectomy erectile dysfunction in men
por: Li, Jinhong, et al.
Publicado: (2014)

Inflammatory biomarkers may predict response to phosphodiesterase type 5 inhibitor treatment in patients with erectile dysfunction
por: Kilic, Metin, et al.
Publicado: (2023)

Future prospects in the treatment of erectile dysfunction: focus on avanafil
por: Alwaal, Amjad, et al.
Publicado: (2011)

Management of male erectile dysfunction: From the past to the future
por: Wang, Chang-Ming, et al.
Publicado: (2023)

Measurement of endothelial dysfunction via peripheral arterial tonometry predicts vasculogenic erectile dysfunction
por: Kovac, Jason R., et al.
Publicado: (2014)

Endothelial Dysfunction and Ischemia-Modified Albumin Levels in Males with Diabetic and Nondiabetic Erectile Dysfunction
por: Kurt, Hasan Anıl, et al.
Publicado: (2022)

Advances in Nanoparticle Delivery System for Erectile Dysfunction: An Updated Review
por: Masuku, Nelisiwe Prenate, et al.
Publicado: (2021)

AB007. Protein therapy to regenerate erectile tissue for future management of erectile dysfunction
por: Ryu, Ji-Kan, et al.
Publicado: (2018)

AB028. Current status of pharmacotherapy for erectile dysfunction
por: Adaikan, P Ganesan
Publicado: (2016)

Hyperhomocysteinemia: Focus on Endothelial Damage as a Cause of Erectile Dysfunction
por: Salvio, Gianmaria, et al.
Publicado: (2021)

Markers of erectile dysfunction
por: Davies, Kelvin P., et al.
Publicado: (2008)

Statins and Erectile Dysfunction
por: Kostis, John B., et al.
Publicado: (2019)

Avanafil for erectile dysfunction
Publicado: (2019)

Erectile dysfunction and the baculum
por: Smith, Theodore C, et al.
Publicado: (2019)

Endocan and Erectile Dysfunction
por: Balta, Sevket, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_geu79bu08seluigtt1cedp65m2